BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17473921)

  • 1. TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.
    Wang FL; Qin WJ; Wen WH; Tian F; Song B; Zhang Q; Lee C; Zhong WD; Guo YL; Wang H
    Cancer Immunol Immunother; 2007 Nov; 56(11):1785-93. PubMed ID: 17473921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice.
    Tian F; Wang L; Qin W; Wang F; Song B; Li Y; Wen W; Zhang Z; Zhu K; Zhang Q; Lee C; Zhong W; Guo Y; Wang H
    Cancer Lett; 2008 Nov; 271(2):333-41. PubMed ID: 18675506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
    Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
    Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine.
    Kao JY; Gong Y; Chen CM; Zheng QD; Chen JJ
    J Immunol; 2003 Apr; 170(7):3806-11. PubMed ID: 12646647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
    Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
    Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy.
    Zhang M; Berndt BE; Chen JJ; Kao JY
    J Immunol; 2008 Sep; 181(5):3690-7. PubMed ID: 18714045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells.
    Thepmalee C; Panya A; Junking M; Chieochansin T; Yenchitsomanus PT
    Hum Vaccin Immunother; 2018 Jun; 14(6):1423-1431. PubMed ID: 29420117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
    Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
    Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
    Mikyšková R; Štěpánek I; Indrová M; Bieblová J; Šímová J; Truxová I; Moserová I; Fučíková J; Bartůňková J; Špíšek R; Reiniš M
    Int J Oncol; 2016 Mar; 48(3):953-64. PubMed ID: 26718011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
    Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
    Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer.
    Zhang P; Wang J; Wang D; Wang H; Shan F; Chen L; Hou Y; Wang E; Lu CL
    Int Immunopharmacol; 2012 Nov; 14(3):252-60. PubMed ID: 22884511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
    Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
    Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-specific disruption of TGF-β receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity.
    Ramalingam R; Larmonier CB; Thurston RD; Midura-Kiela MT; Zheng SG; Ghishan FK; Kiela PR
    J Immunol; 2012 Oct; 189(8):3878-93. PubMed ID: 22972928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.
    Thepmalee C; Panya A; Sujjitjoon J; Sawasdee N; Poungvarin N; Junking M; Yenchitsomanus PT
    Hum Vaccin Immunother; 2020 Oct; 16(10):2318-2327. PubMed ID: 31976810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-tolerance of recipient-derived transforming growth factor-beta dendritic cells.
    Tiao MM; Lu L; Huang LT; Liang CD; Chen CL; Tao R; Fung JJ; Qian S
    Transplant Proc; 2007; 39(1):281-2. PubMed ID: 17275522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.